Explore public concerns about prescription drug costs, the impact of TrumpRx, and the necessity for stronger regulations to ensure affordability for all.

Discover how the Inflation Reduction Act benefits Medicare Part D by reducing prescription costs and improving health outcomes for beneficiaries.

Eli Lilly's weight-loss drug plans face challenges with Medicare's $50 cap on out-of-pocket costs, impacting insurance regulations.

The Supreme Court's rulings and CMS drug price negotiations may impact insurance compliance. Explore regulations affecting the insurance industry today.

Oregon reinstates annual price increase reports for drug pricing transparency. Learn how this affects insurance compliance, risk management, and industry standards.

Discover how PBMs influence Medicare and Medicaid markets, focusing on drug prices, regulation, and accountability in healthcare practices.

Discover how the new federal reforms on pharmacy benefit managers are reshaping health plans and Medicare Part D with a focus on transparency and compliance.

Explore how the 2026 healthcare cost changes will impact insurance, with strategic insights on Medicare, ACA, and new drug pricing structures.

CMS announces changes to Medicare drug price negotiations; ongoing litigation surrounds 340B rebate model and state drug pricing laws, affecting Medicare Advantage plans and Part D reimbursement.

With enhanced ACA subsidies expiring, House Republicans propose expanding employer insurance access and regulating PBMs to address drug costs, while bipartisan efforts seek subsidy extensions.